Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente gegen Schlafstörungen beschrieben. Diese werden entsprechend den DSM-5-Kriterien neu geordnet. Die Strukturen innerhalb der einzelnen Diagnosen sind geblieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Allen RP, Chen C, Garcia-Borreguero D et al (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 370: 621–631
Brown RE, Basheer R, McKenna JT et al (2012) Control of sleep and wakefulness. Physiol Rev 92: 1087–1187
Dauvilliers Y, Bassetti C, Lammers GJ et al; HARMONY I Study Group (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12: 1068–1075
Dresler M, Spoormaker VI, Beitinger P et al (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 141: 300–334
Hornyak M, Scholz H, Kohnen R et al (2014) What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Medicine Rev 18: 153–164
Laudon M, Frydman-Marom A (2014) Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 15(9): 15924–15950
Mayer G (2014) Narkolepsie. Nervenarzt 85: 26–34
Moore TJ, Glemullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174(12): 1930–1933
Nissen C, Frase L, Hajak G, Wetter TC (2014) Hypnotika – Stand der Forschung. Nervenarzt 85: 67–76
Oertel WH, Depboylu C, Kreuzer M et al (2014) REM-Schlaf-Verhaltensstörung als prodromales Stadium von α-Synukleinopathien. Nervenarzt 85: 19–25
Pollmächer T, Wetter TC, Happe S et al (2014) Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Nervenarzt 85: 57–66
Riemann D, Baglioni C, Feige B, Spiegelhalder K (2014) Insomnien – Stand der Forschung. Nervenarzt 85: 43–49
Saper CB, Chou TC, Scammell TE (2001) The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24: 726–731
Schwartz JC (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 63: 713–721
Steiger A, Pawlowski M, Kimura M (2015) Sleep electroencephalography as a biomarker in depression. ChronoPhysiol Ther 5: 15–25
Trenkwalder C, Benes H, Grote L et al, for the RELOXYN Study Group (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12: 1141–1150
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome – current therapies and management of augmentation. Nat Rev Neurol 11(8): 434–445
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Steiger, A., Weber, F., Benkert, O. (2017). Medikamente zur Behandlung von Schlafstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-50333-1_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-50332-4
Online ISBN: 978-3-662-50333-1
eBook Packages: Medicine (German Language)